To spur sales of its poorly selling Alzheimer’s drug, Biogen is cutting the price in half to $28,200 a year per patient
Biogen Inc. is slashing in half the price of its controversial new Alzheimer’s disease treatment, Aduhelm, in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.
when the drug was approved in June, Biogen said Monday.France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Strictly fans say Glitterball trophy should be cut in half after closest finalAfter a super close and emotional final of Strictly Come Dancing, viewers watching at home called for the coveted Glitterball trophy to be shared between the four worthy finalists
Lire la suite »
How To Structure A Permanent Child Tax Credit ExpansionDemocrats must get creative if they want to preserve this critical accomplishment, which helped cut child poverty in half this year.
Lire la suite »
Researchers look to once-taboo frontier — psychedelics — to treat 'anguished' health workersIn a first-of-its kind clinical trial, a research team will treat 30 depressed medical professionals with a dose of synthetic psilocybin — a psychedelic drug — to see if the drug, along with psychotherapy, can reduce their mental anguish.
Lire la suite »
A3 charter school fraud defendant sentenced to probation, fined $300,000Robert Williams cooperated with prosecutors and paid half of his fines at sentencing Friday, prosecutor said.
Lire la suite »
19 Badass Pixie Cuts That Make Me Want to Cut My Hair OffLooks like I'm going to the salon today.
Lire la suite »